Drug transporters in drug disposition – the year 2022 in review

Abstract

On behalf of all the authors, I am pleased to share our third annual review on drug transporter science with an emphasis on articles published and deemed influential in signifying drug transporters’ role in drug disposition in the year 2022. As the drug transporter field is rapidly evolving several key findings were noted including promising endogenous biomarkers, rhythmic activity, IVIVE approaches in transporter-mediated clearance, new modality interaction, and transporter effect on gut microbiome. As identified previously (Chothe et Cal. 2021, 2022) the goal of this review is to highlight key findings without a comprehensive overview of each article and to this end, each coauthor independently selected 1–3 peer-reviewed articles published or available online in the year 2022 (Table 1). Each article is summarized in synopsis and commentary with unbiased viewpoints by each coauthor. We strongly encourage readers to consult original articles for specifics of the study. Finally, I would like to thank all coauthors for their continued support in writing this annual review on drug transporters and invite anyone interested in contributing to future versions of this review.

Keywords:

• Biomarker
• drug-drug interaction
• drug transporters
• PBPK

Disclosure statement

Masanori Nakakariya, Charles J. Rotter, Philip Sandoval and Kimio Tohyama hold common stocks in Takeda Development Center Americas. Paresh P. Chothe and Diane Ramsden hold common stocks in Takeda Development Center Americas and AstraZeneca.